Navigation Links
Neurocrine Biosciences Reports Third Quarter 2013 Results
Date:10/29/2013

e and Boehringer Ingelheim during 2012, as scheduled.

Research and development expenses were $9.5 million during the third quarter of 2013 compared to $9.9 million for the same period in 2012. For the nine months ended September 30, 2013, research and development expenses were $30.3 million, compared to $28.1 million for the same period last year. The increase in year-to-date research and development expenses is primarily due to increased external development costs related to the Company's VMAT2 program (NBI-98854) as it continues through Phase IIb clinical development.

Updated 2013 Financial GuidanceThe Company expects to end 2013 with approximately $145 million in cash, investments and receivables. The net loss for 2013 is expected to be approximately $46 to $47 million, or approximately $0.70 loss per share based on 67 million basic common shares outstanding. The previous financial guidance for 2013 was a net loss of $50 to $55 million with year-end cash, investments and receivables exceeding $130 million.

Pipeline HighlightsElagolix UpdateAbbVie is currently conducting the Violet Petal Study, a Phase III study of elagolix for endometriosis. The study is a 24-week, multinational, randomized, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of elagolix in 875 women, age 18 to 49, with moderate to severe endometriosis-associated pain. Approximately 160 sites in the United States, Puerto Rico and Canada are conducting this study.

AbbVie recently initiated the second Phase III study of elagolix for endometriosis. This study is similar in design to the Violet Petal Study and will assess 788 women, age 18 to 49, with moderate to severe endometriosis-associated pain at more than 200 sites globally.AbbVie is also currently conducting a Phase IIb study of elagolix in uterine fibroids. This study is assessing uterine blood los
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences Reports Second Quarter 2013 Results
2. Neurocrine Biosciences Announces Conference Call And Webcast To Present Second Quarter 2013 Financial Results
3. Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care Conference
4. Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
5. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
6. Neurocrine Biosciences Reports Third Quarter 2012 Results
7. Neurocrine Biosciences Reports Second Quarter 2012 Results
8. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
9. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
10. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
11. Proove Biosciences Will Be Exhibiting At The 2013 Common Sense Pain Management Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Calif. , July 29, 2014  ImmunoClin ... in personalized medicine, treatment of infectious diseases as ... of prognosis and prevention of pathologies like cardiovascular ... August 1, 2014, ImmunoClin Corporation will complete the ... Washington, D.C. , a key center ...
(Date:7/29/2014)... Tenn. (PRWEB) July 29, 2014 ... in biomass feedstock supply innovation and supply chain ... proprietary feedstock management systems, Energy Grange™ and Supply ... of R&D and in-the-field testing aimed at consolidating ... offering benefits to landowners, farmers and feedstock end ...
(Date:7/29/2014)... 2014  United Therapeutics Corporation (NASDAQ: ... results for the second quarter ended June 30, ... that our medicines are reaching increasing numbers ... (PAH)," said Martine Rothblatt, Ph.D., United Therapeutics, ... launch this quarter of our extended-release tablet ...
(Date:7/29/2014)... The prestigious "Discovery or Exploration in History Award" ... Juliana Hillis and Kaylie O’Connell, students at Stoneham High ... Egg, Everything: America’s First IVF Baby". This project was ... History Day program during a week-long final competition judged ... D.C. , The growing popularity of the assisted reproductive ...
Breaking Biology Technology:ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC 2ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC 3Genera Energy Introduces Proprietary Feedstock Management Systems 2Genera Energy Introduces Proprietary Feedstock Management Systems 3Genera Energy Introduces Proprietary Feedstock Management Systems 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 2In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 3
... CINCINNATI, June 16, 2011 Kendle (Nasdaq: ... research organization, today announced several of its senior ... issues at the Drug Information Association (DIA) 47th ... experts will address key topics, including the benefits ...
... , New Generation of the Ziehm Vision RFD ... Imaging has launched a new generation of the Ziehm Vision,RFD ... allows it to be used over an almost unlimited period,of ... ORs.,Thanks to its mobility and significantly lower investment costs,the Ziehm ...
... 2011 NewCardio, Inc., (OTC BB: NWCI) a ... of its recent medical and technical submissions have ... Annual International Conference of the IEEE Engineering in ... The two papers: ,Wireless Monitoring of Reconstructed 12-Lead ...
Cached Biology Technology:Kendle Experts to Address Key Industry Issues at Drug Information Association 47th Annual Meeting 2Kendle Experts to Address Key Industry Issues at Drug Information Association 47th Annual Meeting 3SVS 2011: Ziehm Imaging Presents Latest Mobile C-armTechnology for Intraoperative use 2NewCardio Selected to Present at 33rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society 2NewCardio Selected to Present at 33rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society 3NewCardio Selected to Present at 33rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society 4
(Date:7/28/2014)... pinpointed a mechanism in part of the brain that is ... to both type 1 and type 2 diabetes. The findings ... of the National Academies of Sciences . , "We,ve ... part of the hypothalamus known as the ventromedial nucleus ... levels in the blood," said lead author Sabrina Diano, professor ...
(Date:7/28/2014)... The genome of Solanum pennellii , a wild ... an international group of researchers including the labs headed ... UC Davis Department of Plant Biology. The new genome ... , The work, published July 27 in the journal ... and colleagues at Aachen University in Germany. The UC ...
(Date:7/28/2014)... for Alzheimer,s disease and other forms of dementia, but ... treatment. , University of Washington bioengineers have a designed ... of the body,s normal proteins into a state that,s ... disease, Type 2 diabetes and Lou Gehrig,s disease. The ... their normal state into an abnormally folded form by ...
Breaking Biology News(10 mins):Glucose 'control switch' in the brain key to both types of diabetes 2New protein structure could help treat Alzheimer's, related diseases 2New protein structure could help treat Alzheimer's, related diseases 3
... DigitalPersona, Inc., a leader in fingerprint identity ... Solutions Company is now offering U.are.U fingerprint sensors ... modular point-of-sale (POS) workstation, the Stingray JS-950. The ... can be attached to either side of the ...
... land degradation in dryland regions continuing to worsen, ... on scientist-recommended indicators for monitoring and assessing desertification ... landmark agreement was reached after two weeks of ... attending the Ninth Session of the Conference of ...
... Israel, October 7, 2009 H2 Blocker drugs, such as ... reflux (heartburn), pose no significant risks for the fetus according ... University of the Negev. The study published in the ... the safety of the fetus when H2 blocker drugs ...
Cached Biology News:Panasonic Offers U.are.U(R) Fingerprint Sensor From DigitalPersona on Stingray JS-950 Point-of-Sale Workstations 2Satellite data instrumental in combating desertification 2Satellite data instrumental in combating desertification 3Heartburn drugs deemed safe for fetuses according to Ben-Gurion University researchers 2
Purified Mouse anti-Hu LAT (pY226) Storage Temperature: Refrigerate(2 to 8C)...
Tris-EDTA Buffer Solution, 1X, pH 8.0, sterile, Molecular Biology Grade...
... the most comprehensive, cost-effective solution to ... incorporated unprecedented quality into both our ... proven detection chemistries and antibodies that ... protocol. It also includes our competitively ...
...
Biology Products: